title: Role of the cytoskeleton in mediating effect of vasopressin and herbimycin A on secretory K channels in CCD.
abstract: We have previously demonstrated that inhibiting protein tyrosine kinase (PTK) and stimulating protein kinase A (PKA) increase the activity of the small-conductance K (SK) channel in the cortical collecting duct (CCD) of rat kidneys (Cassola AC, Giebisch G, and Wang WH. Am J Physiol Renal Fluid Electrolyte Physiol 264: F502-F509, 1993; Wang WH, Lerea KM, Chan M, and Giebisch G. Am J Physiol Renal Physiol 278: F165-F171, 2000). In the present study, we used the patch-clamp technique to study the role of the cytoskeleton in mediating the effect of herbimycin A, an inhibitor of PTK, and vasopressin on the SK channels in the CCD. The addition of colchicine, an inhibitor of microtubule assembly, or taxol, an agent that blocks microtubule reconstruction, had no significant effect on channel activity. However, colchicine and taxol treatment completely abolished the stimulatory effect of herbimycin A on the SK channels in the CCD. Removal of the microtubule inhibitors restored the stimulatory effect of herbimycin A. In contrast, treatment of the tubules with either taxol or colchicine did not block the stimulatory effect of vasopressin on the SK channels. Moreover, the effect of herbimycin A on the SK channels was also absent in the CCDs treated with either cytochalasin D or phalloidin. In contrast, the stimulatory effect of vasopressin was still observed in the tubules treated with phalloidin. However, cytochalasin D treatment abolished the effect of vasopressin on the SK channels. Finally, the effects of vasopressin and herbimycin A are additive because inhibiting PTK can still increase the channel activity in CCD that has been challenged by vasopressin. We conclude that an intact cytoskeleton is required for the effect on the SK channels of inhibiting PTK and that the SK channels that are activated by inhibiting PTK were differently regulated from those stimulated by vasopressin.
authors.affiliation: Department of Pharmacology, New York Medical College, Valhalla, New York 10595, USA.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wei
authors.forename: Wen-Hui
authors.initials: WH
authors.lastname: Wang
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D016227:Benzoquinones; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003078:Colchicine / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D003599:Cytoskeleton / Q000502:physiology*; D004594:Electrophysiology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007685:Kidney Tubules, Collecting / Q000187:drug effects / Q000378:metabolism*; D047029:Lactams, Macrocyclic; D008870:Microtubules / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D015221:Potassium Channels / Q000819:agonists*; D024681:Potassium Channels, Calcium-Activated; D011505:Protein-Tyrosine Kinases / Q000494:pharmacology; D011809:Quinones / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017828:Rifabutin / Q000031:analogs & derivatives; D051640:Small-Conductance Calcium-Activated Potassium Channels; D014667:Vasopressins / Q000494:pharmacology*
chemical_list: D000199:Actins; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D015221:Potassium Channels; D024681:Potassium Channels, Calcium-Activated; D011809:Quinones; D051640:Small-Conductance Calcium-Activated Potassium Channels; D014667:Vasopressins; D017828:Rifabutin; C020754:herbimycin; D011505:Protein-Tyrosine Kinases; D017868:Cyclic AMP-Dependent Protein Kinases; D017239:Paclitaxel; D003078:Colchicine